T Spector

2.3k total citations
45 papers, 1.9k citations indexed

About

T Spector is a scholar working on Molecular Biology, Oncology and Epidemiology. According to data from OpenAlex, T Spector has authored 45 papers receiving a total of 1.9k indexed citations (citations by other indexed papers that have themselves been cited), including 24 papers in Molecular Biology, 16 papers in Oncology and 14 papers in Epidemiology. Recurrent topics in T Spector's work include Biochemical and Molecular Research (15 papers), Colorectal Cancer Treatments and Studies (10 papers) and Herpesvirus Infections and Treatments (10 papers). T Spector is often cited by papers focused on Biochemical and Molecular Research (15 papers), Colorectal Cancer Treatments and Studies (10 papers) and Herpesvirus Infections and Treatments (10 papers). T Spector collaborates with scholars based in United States, France and Russia. T Spector's co-authors include P A Furman, M H St Clair, John E. Reardon, David G. Johns, David Porter, D R Averett, Gertrude B. Elion, Thomas Jones, A J Langlois and Wayne H. Miller and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Biological Chemistry and Journal of Clinical Oncology.

In The Last Decade

T Spector

45 papers receiving 1.8k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
T Spector United States 22 731 668 638 423 280 45 1.9k
Thomas P. Zimmerman United States 26 1.1k 1.5× 518 0.8× 277 0.4× 458 1.1× 205 0.7× 68 2.1k
Tammy Krogmann United States 16 979 1.3× 397 0.6× 1.6k 2.5× 341 0.8× 79 0.3× 22 2.4k
Marian Gorecki Israel 31 971 1.3× 302 0.5× 132 0.2× 305 0.7× 312 1.1× 63 2.2k
Robert Cozens Switzerland 18 955 1.3× 190 0.3× 338 0.5× 212 0.5× 92 0.3× 29 1.8k
Hiroo Hoshino Japan 29 746 1.0× 335 0.5× 373 0.6× 458 1.1× 647 2.3× 99 2.3k
Hiroyuki Hayakawa Japan 27 1.1k 1.4× 839 1.3× 358 0.6× 819 1.9× 522 1.9× 91 3.1k
Vincent J. Merluzzi United States 17 558 0.8× 452 0.7× 139 0.2× 762 1.8× 554 2.0× 32 2.2k
D G Johns United States 19 565 0.8× 212 0.3× 156 0.2× 495 1.2× 328 1.2× 27 1.5k
L. Lee Bennett United States 28 1.5k 2.1× 419 0.6× 307 0.5× 494 1.2× 76 0.3× 80 2.3k
Steven Lacy United States 19 333 0.5× 346 0.5× 419 0.7× 134 0.3× 72 0.3× 29 1.2k

Countries citing papers authored by T Spector

Since Specialization
Citations

This map shows the geographic impact of T Spector's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by T Spector with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites T Spector more than expected).

Fields of papers citing papers by T Spector

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by T Spector. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by T Spector. The network helps show where T Spector may publish in the future.

Co-authorship network of co-authors of T Spector

This figure shows the co-authorship network connecting the top 25 collaborators of T Spector. A scholar is included among the top collaborators of T Spector based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with T Spector. T Spector is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Sano, Yasuyo, Elizabeth A. Wilson, Kok‐Fai Kong, et al.. (2025). Pharmacological Characterization of Zasocitinib (TAK-279): An Oral, Highly Selective, and Potent Allosteric TYK2 Inhibitor. Journal of Investigative Dermatology. 146(1). 214–222.e7. 1 indexed citations
2.
Chang, Jae C., et al.. (2012). Abstract OT3-3-01: Eniluracil + 5-fluorouracil + leucovorin (EFL) vs. capecitabine phase 2 trial for metastatic breast cancer. Cancer Research. 72(24_Supplement). OT3–3. 2 indexed citations
3.
Leffert, Janine J., et al.. (1999). In vivo effect of 5-ethynyluracil on 5-fluorouracil metabolism determined by 19F nuclear magnetic resonance spectroscopy.. PubMed. 59(1). 122–7. 29 indexed citations
4.
Fischel, Jean–Louis, Patricia Formento, Marie‐Christine Etienne, et al.. (1997). Dual modulation of 5-fluorouracil cytotoxicity using folinic acid with a dihydropyrimidine dehydrogenase inhibitor. Biochemical Pharmacology. 53(11). 1703–1709. 14 indexed citations
5.
6.
Baker, Sharyn D., S P Khor, Alex A. Adjei, et al.. (1996). Pharmacokinetic, oral bioavailability, and safety study of fluorouracil in patients treated with 776C85, an inactivator of dihydropyrimidine dehydrogenase.. Journal of Clinical Oncology. 14(12). 3085–3096. 117 indexed citations
7.
Fischel, Jean–Louis, M C Etienne, T Spector, et al.. (1995). Dihydropyrimidine dehydrogenase: a tumoral target for fluorouracil modulation.. PubMed. 1(9). 991–6. 57 indexed citations
8.
Spector, T, et al.. (1995). Attenuation of the antitumor activity of 5-fluorouracil by (R)-5-fluoro-5,6-dihydrouracil.. PubMed. 55(6). 1239–41. 58 indexed citations
9.
Spector, T, David Porter, Donald J. Nelson, et al.. (1994). 5-Ethynyluracil (776C85), a modulator of the therapeutic activity of 5-fluorouracil. Drugs of the Future. 19(6). 565–565. 40 indexed citations
10.
Clair, M H St, Lloyd Frick, T Spector, et al.. (1993). Novel 6-alkoxypurine 2',3'-dideoxynucleosides as inhibitors of the cytopathic effect of the human immunodeficiency virus. Journal of Medicinal Chemistry. 36(3). 378–384. 19 indexed citations
11.
Spector, T, David C. Lobe, Mark Ellis, Todd A. Blumenkopf, & George M. Szczech. (1992). Inactivators of herpes simplex virus ribonucleotide reductase: hematological profiles and in vivo potentiation of the antiviral activity of acyclovir. Antimicrobial Agents and Chemotherapy. 36(5). 934–937. 22 indexed citations
12.
Baum, Kenneth F., Randolph L. Berens, J. Joseph Marr, Joan A. Harrington, & T Spector. (1989). Purine deoxynucleoside salvage in Giardia lamblia. Journal of Biological Chemistry. 264(35). 21087–21090. 23 indexed citations
13.
Spector, T, D R Averett, Donald J. Nelson, et al.. (1985). Potentiation of antiherpetic activity of acyclovir by ribonucleotide reductase inhibition.. Proceedings of the National Academy of Sciences. 82(12). 4254–4257. 51 indexed citations
14.
Spector, T & Thomas Jones. (1985). Herpes simplex type 1 ribonucleotide reductase. Mechanism studies with inhibitors.. Journal of Biological Chemistry. 260(15). 8694–8697. 18 indexed citations
15.
Spector, T & Robert Ferone. (1984). Folic acid does not inactivate xanthine oxidase.. Journal of Biological Chemistry. 259(17). 10784–10786. 20 indexed citations
16.
Averett, D R, P A Furman, & T Spector. (1984). Ribonucleotide reductase of herpes simplex virus type 2 resembles that of herpes simplex virus type 1. Journal of Virology. 52(3). 981–983. 16 indexed citations
17.
Furman, P A, M H St Clair, & T Spector. (1984). Acyclovir triphosphate is a suicide inactivator of the herpes simplex virus DNA polymerase.. Journal of Biological Chemistry. 259(15). 9575–9579. 163 indexed citations
18.
Spector, T. (1975). Studies with GMP synthetase from Ehrlich ascites cells. Purification, properties, and interactions with nucleotide analogs.. Journal of Biological Chemistry. 250(18). 7372–7376. 24 indexed citations
19.
Spector, T & David G. Johns. (1970). 4-Hydroxypyrazolo(3,4-d)pyrimidine as a substrate for xanthine oxidase: Loss of conventional substrate activity with catalytic cycling of the enzyme. Biochemical and Biophysical Research Communications. 38(4). 583–589. 16 indexed citations
20.
Spector, T & David G. Johns. (1970). Stoichiometric Inhibition of Reduced Xanthine Oxidase by Hydroxypyrazolo[3,4-d]pyrimidines. Journal of Biological Chemistry. 245(19). 5079–5085. 76 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Thomas P. Zimmerman Breakdown of academic impact, for papers by Tammy Krogmann Breakdown of academic impact, for papers by Marian Gorecki Breakdown of academic impact, for papers by Robert Cozens Breakdown of academic impact, for papers by Hiroo Hoshino Breakdown of academic impact, for papers by Hiroyuki Hayakawa Breakdown of academic impact, for papers by Vincent J. Merluzzi Breakdown of academic impact, for papers by D G Johns Breakdown of academic impact, for papers by L. Lee Bennett Breakdown of academic impact, for papers by Steven Lacy
Rankless by CCL
2026